Empowering Discovery,
Enhancing Knowledge

InLighta BioSciences, a start-up company led by Jenny Yang, Regents’ Professor of Chemistry at Georgia State University, has been awarded an NIH grant to accelerate development of a magnetic resonance imaging contrast agent to detect liver fibrosis.

Health Imaging recently reported InLighta’s development of a protein-based MRI contrast agent designed to target liver cancer biomarkers for earlier cancer detection.

A study reporting a new method to detect early-stage liver cancer was recently published in the journal Science Advances. This method uses a protein-based MRI contrast agent targeting the CXCR4 receptor associated with certain metastatic cancer cells, and a new precision MRI (pMRI) imaging methodology, to enable earlier detection of cancer. Early detection is expected to result in better treatment options and improved patient outcomes.

This new technology was developed in the lab of Dr. Jenny Yang at Georgia State University, and collaborator’s from Emory University, and was recently featured in a GSU media release.

Nature Reviews Gastroenterology and Hepatology recently published a review about InLighta’s collagen-targeted MRI contrast agent for liver fibrosis, which provides direct quantification of collagen deposition in preclinincal liver disease models.